RaQualia Pharma Inc.
RaQualia Pharma Inc. (JPX: 4579) is trading at ¥620.00, about ₹378 at today's JPY/INR rate, as of 30 Sep 2026, 2:23 AM ET, up 4.38% today. Indian residents can buy RaQualia Pharma from India on Paasa under the RBI's Liberalised Remittance Scheme.
Quote
Today's low
¥603.00
Today's high
¥624.00
52 week low
¥438.00
52 week high
¥1,465.00
4579 opened at ¥604.00, closed previously at ¥594.00, and has traded between ¥438.00 and ¥1,465.00 over the past 52 weeks.
About
RaQualia Pharma Inc., established in 2008 and based in Nagoya, Japan, is a pharmaceutical company dedicated to the global research and development of innovative drug compounds. Its human therapeutic pipeline features several key candidates. Tegoprazan, designed to treat gastroesophageal reflux disease (GERD), is currently undergoing Phase 1 clinical trials in the United States. Grapiprant is in Phase II development in the U.S. and Phase I in China for pain management; it is also being investigated in Phase I studies in both the U.S. and China for its potential in cancer therapy. Beyond human medicines, RaQualia Pharma develops a range of veterinary products. These include grapiprant for managing osteoarthritis in dogs, a ghrelin receptor agonist aimed at addressing cancer-related anorexia/cachexia syndrome and constipation stemming from spinal cord injury, and ELURA, a medication for combating weight loss in cats suffering from chronic kidney disease. The company's extensive R&D pipeline also covers various other therapeutic areas. This includes a TRPM8 blocker for neuropathic pain, a motilin receptor agonist targeting gastrointestinal motility disorders such as gastroparesis, functional dyspepsia, and post-operative ileus, and a potassium-competitive acid blocker for GERD, which has successfully concluded Phase 1 clinical trials. Further early-stage developments encompass a 5-HT4 partial agonist for gastroparesis, functional dyspepsia, and chronic constipation; a 5-HT2B antagonist for irritable bowel syndrome with diarrhea; EP4 antagonists for canine pain management and, in separate Phase I trials, for cancer and general pain indications; a serotonin 5-HT2A and dopamine D2 receptor blocker for schizophrenia; a Cyclooxygenase-2 inhibitor (Phase I for pain); a CB2 agonist; a selective sodium channel blocker; a P2X7 receptor antagonist (Phase I for neuropathic pain); and a retinoic acid receptor alpha agonist. To further its research and development initiatives, RaQualia maintains strategic partnerships with Interprotein Corporation, ASKA Pharmaceutical Co., Ltd., and Epigeneron, Inc.
Key statistics
Avg. volume
194.13K
Market cap
¥15.16B
P/E Ratio
69.27
Price-to-sales ratio
3.89
Enterprise value
¥23.59B
Free cash flow yield
-1.77%
Debt-to-equity ratio
0.34
Return on equity
3.96%
ROIC
3.07%
Beta
0.91
Dividend yield
0.00%
Last dividend
¥0.00
Financial overview
Revenue
¥3.98B
Earnings per share
¥11.53
Free cash flow
-¥423.98M
Net profit margin
4.13%
Gross margin
79.46%
EBITDA
¥985.17M
Revenue growth
28.07%
Similar securities
This is not an investment recommendation
How to buy RaQualia Pharma from India
Indian residents can buy RaQualia Pharma shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.
Open a Paasa account
Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Add funds under LRS
Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars and then to JPY.
Search for RaQualia Pharma and place an order
Find RaQualia Pharma by name or by its ticker, 4579, and choose an order type. The Tokyo Stock Exchange typically trades in units of 100 shares. RaQualia Pharma trades 5:30 am – 12:00 pm IST; orders can only execute during that window.
Track holdings and download tax reports
Follow your RaQualia Pharma position in JPY and INR. RaQualia Pharma pays no dividend today, so your filing is the capital-gains statement plus the Schedule FA holding line.
Read the full guide: how to invest in RaQualia Pharma from India
Trading and taxes when buying RaQualia Pharma from India
Trading and limits
- Trading hours
- 9:00 am – 3:30 pm JST
- LRS limit
- $250,000Per financial year, under the RBI's Liberalised Remittance Scheme.
Tax for Indian residents
- TCS on remittance
- 20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
- Capital gains in India
- 12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
- Dividends
- NoneRaQualia Pharma does not currently pay a dividend. If it starts, dividends are taxed at your slab rate in India.Dividend tax explained
- Estate or inheritance tax
- May applyJapan levies inheritance tax on Japan-located assets such as direct stocks, with an exemption of ¥30 million plus ¥6 million per statutory heir.Estate tax explained
Custody. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.
FAQs
Can Indian residents buy RaQualia Pharma stock?
Yes. RaQualia Pharma (4579) has been listed on the Tokyo Stock Exchange since 2011, in the Biotechnology industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars and then to JPY. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.
How much does one RaQualia Pharma share cost in rupees?
One RaQualia Pharma share is ¥620.00 — about ₹378 at a JPY/INR rate of 0.6103 on 29 Sep 2026. Both the RaQualia Pharma price and the rupee rate move during the day, so the rupee cost changes with them.
What are the LRS and TCS rules for buying RaQualia Pharma from India?
Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.
What is the minimum I can buy of RaQualia Pharma?
The Tokyo Stock Exchange typically trades in units of 100 shares.
How are gains on RaQualia Pharma shares taxed in India?
Japan generally does not levy capital gains tax on non-resident individual investors, so the tax is an India-side one. Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the JPY/INR rate on the purchase and the sale date, so the rupee move counts alongside the RaQualia Pharma price. Paasa issues a capital-gains statement for your return.
Does RaQualia Pharma pay a dividend?
No. RaQualia Pharma does not currently pay a dividend, so holding it produces no dividend income to declare in India. If it starts paying one, the Indian treatment is the usual one — dividends are taxed at your slab rate in India — and Paasa's dividend report would show the gross amount and any tax withheld.
When can I trade RaQualia Pharma from India?
The Tokyo Stock Exchange trades 5:30 am – 12:00 pm IST in Indian time. It also halts for lunch, 8:00 am – 9:00 am IST. Orders can only execute during that window.
Is there estate or inheritance tax on RaQualia Pharma shares held from India?
Japan levies inheritance tax on Japan-located assets such as direct stocks, with an exemption of ¥30 million plus ¥6 million per statutory heir. It applies to your overall holdings in that jurisdiction rather than to any one position.
Do I have to declare RaQualia Pharma shares in my Indian tax return?
Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your RaQualia Pharma holding, its cost and its closing value.
How do I sell RaQualia Pharma and bring the money back to India?
You sell during market hours (5:30 am – 12:00 pm IST) and the proceeds settle in JPY in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.